secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMARIN CORP PLCUK (AMRN)
CIK:        0000897448
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0000950170-22-000201
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amarin reports preliminary 2021 revenue ~$580M, appoints Per Wold-Olsen to board
--------------------------------------------------------------------------------

- Full-year 2021 net revenue ~$580M; Q4 revenue ~$140M, stable vs Q3.
- Ended 2021 with ~$490M cash/investments and no debt.
- Plans to develop fixed-dose combination of VASCEPA and a statin.
- Per Wold-Olsen appointed to Board effective Jan 10, 2022; receives $540K in equity awards.
- 2022 revenue guidance not provided due to COVID/generic uncertainty; US ops expect positive contribution margin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/897448/000095017022000201/0000950170-22-000201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/897448/000095017022000201/amrn-20220109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-000201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer